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Abstract 
 
Previous work has shown that the evolution of both insulin-like growth factor 1 (IGF1) and 
insulin shows an episode of accelerated change on the branch leading to New World monkeys 
(NWM).  Here the possibility that this is accompanied by a corresponding episode of 
accelerated evolution of IGF1 receptor (IGF1R), insulin receptor (IR) and/or IGF binding 
proteins (IGFBPs) was investigated. Analysis of receptor sequences from a range of primates 
and some non-primate mammals showed that accelerated evolution did indeed occur on this 
branch in the case of IGF1R and IR, but not for the similar insulin receptor-related receptor 
(IRRR) which does not bind insulin or IGF1. Marked accelerated evolution on this branch 
was also seen for some IGFBPs, but not the mannose 6-phosphate/IGF2 receptor or epidermal 
growth factor receptor. The rate of evolution slowed before divergence of the lineages leading 
to the NWM for which sequences are available (Callithrix and Saimiri).  For the IGF1R and 
IR the accelerated evolution was most marked for the extracellular domains (ectodomains). 
Application of the branch-sites method showed dN/dS ratios significantly greater than 1.0 for 
both receptor ectodomains and for IGFBP1, and allowed identification of residues likely to 
have been subject to selection.  These residues were concentrated in the N-terminal half of the 
IGF1R ectodomain but the C-terminal half of the IR ectodomain, which could have 
implications for the formation of hybrid receptors. Overall the results suggest that adaptive 
coevolution of IGF1, insulin and their receptors and some IGFBPs occurred during the 
evolution of NWM.  For the most part, the residues that change on this branch could not be 
associated with specific functional aspects (ligand binding, receptor dimerization, 
glycosylation) and the physiological significance of this coevolution remains to be 
established. 
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1. Introduction 
In primates the sequences of IGFs and insulin are strongly conserved, except on the lineage 
leading to New World monkeys (NWM), where for both insulin and IGF1 an episode of rapid 
evolution occurred [1-4]. As a consequence the sequence of each hormone in NWM differs 
markedly from that in other primates. A corresponding burst of change is not seen for IGF2, 
but a single substitution may have functional significance [4]. For insulin the rapid evolution 
has led to a change in its receptor-binding and biological activity in NWM, though the full 
significance of this is not clear [1]. These observations suggest that on the lineage leading to 
NWM there was a coevolution of the insulin and IGF1 genes, perhaps associated with a 
change in the relative roles of these molecules in regulation of metabolism and growth [4]. 
The question then arises as to whether associated changes also occurred in the receptors for 
these hormones, and the binding proteins with which IGFs associate. 
 
The insulin receptor (IR) and IGF1 receptor (IGF1R) are large, 2-chain, membrane-spanning 
glycoproteins, possessing intrinsic tyrosine kinase activity and widely distributed in target 
tissues [5-7]. They are structurally similar (about 56% overall sequence identity) [5], and also 
similar to the insulin receptor-related receptor (IRRR) [8], which does not bind insulin or IGF 
and may act as an alkali sensor regulating bicarbonate excess [9] and/or function in male 
sexual differentiation [10].  The genes for IR, IGF1R and IRRP in mammals are large and 
comprise 21-23 exons. In each case a single precursor is cleaved to give the two chains (α and 
β), which remain attached via cystine bridging and exist in the plasma membrane as cystine-
linked dimers. In many mammals the IR gene is subject to alternative splicing, with exon 11 
(36 nucleotides) being included (IR-B) or excluded (IR-A). The proportions of the two forms 
vary according to tissue of expression and developmental stage [11,12]. IR-B binds primarily 
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insulin, IR-A both insulin and IGF2 while IGF1R has high affinity for IGF1 and IGF2 and 
much lower affinity for insulin [12,13].  
 
Structural studies on the IR and IGF1R [14-17] have revealed a similar overall domain 
organization. The ectodomain of the receptor forms an inverted V, with three fibronectin-III-
like (FnIII) domains on the C-terminal arm of the V and leucine rich 1 (LR1), cystine rich 
(CR) and leucine rich 2 (LR2) domains on the N-terminal arm.  In the dimer the FnIII 
domains of one monomer are closely associated with LR1, CR and LR2 of the other.  Hybrid 
dimers (one IR monomer and one IGF1R monomer) can form, and may be of physiological 
significance [18,19].  The dimeric insulin receptor ectodomain has two equivalent ligand 
binding sites, both involving contributions from each monomer [20,21] and showing negative 
cooperativity.  Insulin and IGFs each contain two receptor-binding regions. One of these (site 
1), binds to a site on the receptor including LR1 from one monomer and αCT (at the C-
terminus of the receptor α chain) on the second.  For insulin, binding site 1 was recently 
defined in detail [22]. Site 2 on insulin/IGF appears to bind to a less well-defined site around 
the FnIII-1/FnIII-2 interface on the second monomer; for IR, alanine scanning data have 
partially identified this site [23], but there are no equivalent data for IGF1R.  
 
IGFBPs comprise a family of six main proteins with high affinity for IGF1 and IGF2, but not 
for insulin.  They are produced in many locations and are found in the circulation and in many 
tissues. They modulate the actions of IGFs in various ways, increasing activity by extending 
half life and promoting tissue location, but decreasing activity by blocking receptor binding. 
They also have IGF-independent activities [24,25]. Each IGFBP comprises three domains, the 
N- and C-domains binding to separate sites on IGF, while the linker- (L-) domain provides 
sites for proteolytic cleavage and tissue location. The structures of N- and C-domains of 
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various IGFBPs have been determined, and these and mutational studies have defined the IGF 
binding sites [26,27]. 
 
The recent availability of extensive genomic and transcriptomic data potentially increases 
substantially the sequence data available for insulin, IGFs, their receptors and IGFBPs.  
Recently the genomic sequence of a NWM, the marmoset (Callithrix jacchus) has been 
described in detail [28] providing evidence for rapid evolution of several proteins involved in 
growth regulation, including IGF1R and IGFBP2; this was linked to the reduction in size seen 
in the callitrichine NWM (marmosets and tamarins) [28,29]. Here sequences of the IGF1R, 
IR, IRRR and IGFBPs of primates and several non-primate outgroups have been derived from 
available databases, and examined in order to investigate further which of these proteins 
showed an episode of rapid evolution on the lineage leading to NWM, alongside the 
accelerated evolution noted previously for their cognate ligands [4]. 
 
2. Methods 
2.1. Data 
Sequences of IGF1R, IR, IRRR, IGFBPs, epidermal growth factor receptor (EGFR) and 
cation independent mannose 6-phosphate/IGF2 receptor (M6P/IGF2R) for a wide range of 
primates and some non-primate mammals were obtained from genomic and transcriptomic 
databases, as detailed in Supplementary Table S1 (IGF1R, IR, IRRR), Supplementary Table 
S2 (IGFBPs) and Supplementary Table S3 (EGFR, M6P/IGF2R). Sequences encoding signal 
peptides were not available for all species, so analyses were confined to mature proteins. 
Likewise, for some species exon 11 of IR could not be identified, and analyses were carried 
out on the exon 11 minus (IR-A) form of the receptor.  
 
	   6	  
2.2. Sequence Analysis 
Alignments of nucleotide (coding) and protein sequences were obtained using clustalw [30], 
with manual adjustment where appropriate. Phylogenetic analysis to determine branch lengths 
was carried out using the codeml programme in paml [31] using amino acid sequences and a 
defined tree based on conventional understanding of primate phylogeny [32,33].   To assess 
the variability of sequence evolution the ratio between nonsynonymous and synonymous 
nucleotide substitutions (dN/dS) was used. Synonymous substitutions do not affect the protein 
sequence, and are therefore not subject to the selective constraints maintaining protein 
structure in evolution [34] . The dN/dS ratio therefore gives an indication of the rate of 
protein evolution relative to the underlying ‘neutral’ rate. The significance of elevated dN/dS 
ratios on the branch to NWM was tested using the likelihood ratio test, comparing model 2 
(two dN/dS ratios) with model 0 (one dN/dS ratio) [31]. 
 
Whether variable rates reflected adaptive evolution was investigated using alignments of 
coding sequences and the branch-site method, Model A of the codeml programme [31,35]; 
whether dN/dS was significantly greater than 1.0 was tested using the likelihood ratio test, 
and a null model in which dN/dS was fixed at 1.0. 
 
2.3. Structural models 
Substitutions on the branch to NWM were mapped onto 3-dimensional models of the IR (pdb 
entries 2DTG and 3LOH respectively) [16,36] and IGFBP1 and 4 (pdb entries 1DSQ and 
2DSR) [27] using PyMol (The PyMOL Molecular Graphics System, Version 1.3, 
Schrödinger, LLC). 
 
3. Results and discussion 
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3.1. Episodic evolution of IGF1 and insulin receptors in mammals. 
Sequences of primate IGF1Rs, IRs and IRRRs were derived from available sequence 
databases (Supplementary Table S1). These were aligned using clustalw. Alignments of 
mature proteins (Supplementary Figs. S1-S3) were subjected to phylogenetic analysis, using 
the codeml programme and a defined tree. Fig. 1 shows trees constructed using the protein 
sequences, with branch lengths based on numbers of substitutions.  It is clear that the rate of 
evolution increased markedly on the branch leading to NWM for both IGF1R and IR but not 
for IRRR, although overall IRRR is less conserved than IR or IGF1R.  This suggests that the 
accelerated evolution seen previously on this branch for insulin and IGF1 ([4] and confirmed 
by trees included in Fig. 1) was accompanied by a corresponding acceleration in the rate for 
the receptors of these molecules, but not for IRRR which does not bind either IGFs or insulin. 
The accelerated evolution of IGF1R seen here accords with previous reports [28,29]. 
 
Also showing a fairly high rate of evolution in the trees for IR, IGF1R and IRRR in Fig. 1 are 
the branches to rodents, Cavia and Mus. This may reflect the relatively rapid molecular 
evolution seen generally in rodents [37]. Notably, for IR, the rate for Cavia is only slightly 
higher than that for Mus, despite the very high rate seen for Cavia (and other hystricognath 
rodents) for insulin itself, but not IGF1.  For IGF1R the branch leading to rabbit 
(Oryctolagus) also shows a relatively rapid evolution. 
 
The sequences of IR and IGF1R can be divided into 2 major regions, with clearly distinct 
functions -  extracellular domain (ecd; ectodomain; ligand binding) and intracellular domain 
(icd; signal transduction). Is the accelerated evolution seen on the branch to NWM spread 
across both of these, or associated mainly with one part of the molecule?    It is clear from 
Fig. 2 that the accelerated evolution is associated primarily with the ectodomain (~14-fold 
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increase in rate), though a smaller rate increase (2-3-fold) is also seen for the intracellular 
domain.  The relatively high evolutionary rate (long branch lengths) for rodents is again seen 
for the trees in Fig. 2.  The branch for Cavia is only modestly longer than that for Mus in IR 
ectodomain, but notably in every other tree the Mus branch is longer than the Cavia branch, 
suggesting that there may have been an increase in evolutionary rate for the Cavia branch in 
IR ectodomain, though this is modest compared with the increased rate for insulin itself.  The 
increased evolutionary rate for Oryctolagus IGF1R noted above is seen to be most marked for 
the intracellular domain (Fig. 2). 
 
3.2. Significance of the accelerated evolution of IGF1R and IR 
An episode of rapid evolution could be due to relaxed purifying selection, presumably 
reflecting loss of function, or to selection/adaptive change, reflecting a gain or change in 
function.  Rather little information is available about the functioning of the IR or IGF1R or 
their ligands in NWM.  A NWM (owl monkey, Aotus trivirgatus) insulin had lowered 
potency (about 20% that of human insulin) for binding to human IR [1]; binding to IR from 
NWM was not investigated. However, several considerations support the idea that the 
accelerated evolution of the genes for insulin, IGF1 and their receptors on the branch leading 
to NWM is adaptive in nature.  (1) In the receptors the change is associated primarily with the 
extracellular domain; if an increased evolutionary rate resulted from loss of function one 
might expect it to be more evenly distributed across the whole molecule.  (2) Following the 
episode of rapid evolution, the rate appears to decrease markedly. Thus, the divergence time 
for Platyrrhini/Catarrhini (NWM/Old World monkeys and apes) is ~45 million years ago 
(MYA) and for Saimiri/Callithrix ~19 MYA [38-41]. In Fig. 1, data for IRRR accord with 
these timings, with the average branch length following the Callithrix/Saimiri split being 
slightly shorter than that preceding it. However,  for IR and IGF1R the branch preceding the 
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Callithrix/Saimiri split is 10-16 times longer than the branches to Callithrix/Saimiri.  This 
would accord with a change in function during the period of accelerated evolution, followed 
by a return to stringent purifying selection associated with retention of the changed function.  
(3) Both insulin and IGF1 are crucial physiological regulators. While it is conceivable that 
loss of function of one of them could occur during the course of evolution, loss of function of 
both on a single lineage would be an extraordinary coincidence. 
 
A statistical test of the significance of an episode of accelerated evolution can be performed 
by studying the ratio of nonsynonymous to synonymous substitutions (dN/dS). The former 
affect protein sequence and are normally subject to stringent purifying selection, while the 
latter have no effect on protein sequence and are thought to be largely adaptively neutral and 
little affected by purifying selection [42].  As a consequence, for most genes, most of the 
time, dN/dS is << 1.0. If a gene loses function and purifying selection no longer applies, 
dN/dS is expected to approach 1.0.  For a gene showing adaptive evolution (positive 
selection) dN/dS is expected to increase.  If dN/dS significantly exceeds 1.0 positive selection 
is clearly established, though failure to reach this statistical level does not prove that the 
change is not adaptive. 
 
dN/dS ratios were determined for branches on the phylogenetic trees for IGF1R, IR and IRRR 
constructed from alignments of coding sequences for the mature proteins. Overall dN/dS was 
low, as expected, confirming stringent purifying selection. dN/dS increased significantly on 
the branch to NWM for IR (9 fold) and IGF1R (9 fold) but not for IRRR (Table 1). The effect 
for IR and IGF1R was more marked if just the ectodomain was considered (13 and 16-fold 
increase in dN/dS respectively), but the values of dN/dS were not greater than 1.0, so clear 
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evidence for positive selection is not provided.  Increases for the intracellular domain, were 
more modest, 3.7 and 2.6 fold for IR and IGF1R respectively, but still significant. 
 
The branch-sites method in codeml [35] provides a discriminating test for positive selection at 
specific sites on a specified branch on a phylogenetic tree. Applying this method to the trees 
for IR and IGF1R ectodomain coding sequences identified in each case a considerable 
number of sites (55 and 60 respectively) on the branch leading to NWM that were potentially 
subject to positive selection (Supplementary Table S4).  The overall dN/dS values for these 
sites were significantly greater than 1.0 for the ectodomains of both IR (dN/dS = 2.42; 2 x 
Δlog likelihood (lnL) = 3.89; p< 0.05) and IGF1R (dN/dS= 3.35; 2 x ΔlnL = 8.68; p<0.01).  
The result provides clear-cut evidence for positive selection on the branch leading to NWM 
for both IR and IGF1R. 
 
3.3. Distribution of substitutions in the ectodomains of IGF1R and IR 
The branch-sites method identified 55-60 sites in the ectodomains of IR and IGF1R 
(Supplementary Table S4) that are likely to have evolved by positive selection on the branch 
leading to NWM. These sites corresponded closely with those identified as changing on this 
branch by visual inspection of sequences.  In order to investigate the potential role of these 
sites in the functioning of the receptors, their positions within the 3D structure of the 
extracellular domains were examined.   
 
The sites changing on the branch to NWM were mapped onto the 3D structure of the insulin 
receptor ectodomain (Fig. 3); in the case of IGF1R equivalent sites in the IR were mapped, 
based on sequence alignment of IR and IGF1R.  In each case changes are seen in all 6 
domains of the ectodomain, but there is a marked difference between IR and IGF1R for these 
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changing sites. The number of changes is similar for the IR (55 residues) and IGF1R (60 
residues), but for IR the majority of changing sites (62%) fall in the C-terminal half of the 
receptor ectodomain (Fn-III-1, Fn-III-2 and Fn-III-3) while for IGF1R the majority (67%) are 
in the N-terminal half (LR1,CR, LR2). The difference is statistically significant (Fisher's 
Exact Test, P<0.005). For the IR, the Fn-III-2 domain (including the region of the insert 
domain around the cleavage point, which is mostly not included in the crystal structure) 
showed the most changes, while for IGF1R it was the CR domain (Fig. 3). 
 
This difference between the regions of the IR and IGF1R showing most changes on the 
lineage to NWM could be of significance for the formation of heterodimers between IR and 
IGF1R, since here the regions showing most changes (N-terminal half of extracellular domain 
for IGF1R, C-terminal half for IR) will be apposed in the dimer, as will the corresponding 
regions showing fewest changes. 
 
3.4. Functional aspects of substitutions in the ectodomains of IGF1R and IR 
Ligand-binding sites. The sites on IGF1R and IR involved in binding ligand have been 
investigated by site-directed mutagenesis [23,43,44], computer modelling [45,46] and, in the 
case of IR, crystallography of insulin-receptor complexes [22]. Two main sites have been 
identified, involving both chains and corresponding to two binding sites on the ligands. In IR 
site 1 involves mainly LR1 and αCT, while site 2 involves domains Fn-III-1 and Fn-III-2 and 
possibly LR2.  Site 1 is little changed on the branch to NWM, and none of the key residues 
identified as involved in insulin binding appears to be altered on this branch. However, 
residue 715 in αCT, immediately following F714 which appears to be crucial for insulin 
binding, does change (Val in human, Ile in NWM); conversion of this residue to Ala leads to 
lowered insulin binding [47].  In the case of site 2 several residues in domains Fn-III-1 and 
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Fn-III-2 are changed on the branch to NWM, and one of these, residue 591 (Asp in human, 
Ala in NWM) has been shown by mutation to Ala to be important for insulin binding [23].  
 
For IGF1R, again domains L1 and αCT have been shown by alanine scanning to be involved 
in site 1 binding [43], but also CR which appears to play a part in binding of IGF1 but not 
IGF2 [48]. For  L1 and αCT there are few changes on the branch leading to NWM and none 
of these coincides with a residue identified as involved in IGF binding. For CR many residues 
change on the branch to NWM (see above).  None of these has been implicated in IGF1 
binding by alanine scanning studies, though, in the homology model for IGF-receptor 
complex [46] several were implicated in the ligand/receptor interface.   Site 2 for IGF1R has 
not been identified experimentally, but the homology model places it on Fn-III-1 and Fn-III-2, 
as for insulin.  A number of residues changing on the branch to NWM are located in this 
region, two of which are implicated in ligand-receptor interaction in the homology model 
[46]. 
 
Dimerization. A set of residues that is clearly important for effective functioning of IR and 
IGF1R is that involved in dimerization.  The IR ectodomain structure 3LOH.pdb [36] was 
used to investigate this, identifying those residues in one monomer that contact (are within 4Å 
of) the second monomer. 69 such residues were identified, although this may not be a 
complete list since some regions of the ectodomain are not defined in this structure. Only two 
of these were residues that change on the branch to NWM, suggesting that the interface 
between monomers does not change much during this episode of rapid evolution.  An 
equivalent structure is not available for the IGF1R, but identifying sites potentially involved 
in dimerization on the basis of alignment of IR and IGF1R, again showed that only two of 
these sites changed during the period of accelerated evolution on the branch leading to NWM.  
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It is notable that when IR and IGF1R are compared these 69 interface sites are poorly 
conserved. Only 32 (46%) are identical, compared with 59% overall identity for the two 
receptors, suggesting that there may be substantial differences between the modes of 
dimerization of IR and IGF1R. This could be important in regulating formation of cross-
hybrids between IR and IGF1R, though it is known that such hybrids do form, and may be of 
physiological importance [13,18,19]. 
 
Glycosylation. Glycosylation plays an important role in the structure and function of IR and 
IGF1R.  About 17 Asn residues are N-glycosylated in the IR ectodomain [49], and a similar 
number are potentially glycosylated in the IGF1R ectodomain.  In IR the crucial motif for the 
N-glycosylation site (Asn-X-Ser/Thr) is retained on the branch to NWM in every case; at one 
site Thr is replaced by Ser, but this should not affect glycosylation. For IGF1R, at one site 
Asn is replaced by Asp on the branch to NWM, which would prevent glycosylation; again 
Thr replaces Ser at one site. There are also 6 sites that are O-glycosylated in human IR, all 
near the N-terminus of the β-chain [50]; these do not appear to be essential for receptor 
assembly, ligand binding or receptor autophosphorylation. One of these sites changed (Thr -> 
Met) on the branch to NWM, while for a second a substitution is seen within NWM.  The 
equivalent region in IGF1R appears to be less extensively O-glycosylated, but the extent of 
this is not fully established. 
 
Conformational changes. Conformational changes follow binding of ligands to IR and 
IGF1R, and are important in transduction of signal and in negative cooperativity. Details of 
the structural changes involved are poorly understood. The C-terminal segment of the α chain 
of IR, αCT, appears to play an important role in signal transduction as well as insulin binding 
[47].  The region of αCT involved in insulin binding is mostly unchanged on the branch 
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leading to NWM, except for the most C-terminal residue (Val in human, Ile in NWM), but 
there are several changes in the sequence immediately following this, preceding the cleavage 
site. Whether these are involved in signal transduction is unclear - they are not defined in the 
crystallographic structure.  The structural basis of negative cooperativity is not well defined, 
and it is not possible to establish whether residues involved in this include those that changed 
along the branch to NWM. 
 
Naturally-occurring  mutants. Over 100 human IR mutants associated with insulin resistance 
are listed in the Human Gene Mutation Database [51].  Of  about 60 sites in the ectodomain 
where missense mutations or single amino acid deletions have been described (all of which 
have significant clinical consequences), only one coincides with a site that changes on the 
branch to NWM, a mutation at position 879, in the FnIII-3 domain (mutation Ala -> Gly, 
causing non-insulin dependent diabetes; change Ala -> Thr on branch to NWM).  Fewer 
human IGF1R mutations have been reported [51]. Of about 15 sites where missense 
mutations or single amino acid deletions have been described, most are associated with 
growth retardation, but 4 are associated with longevity [52]. One of the latter sites coincides 
with a site that changes on the branch to NWM. 
 
3.5. IGFBPs 
Coding sequences for the six main IGFBPs were aligned and translated. Protein sequence 
alignments for mature proteins were used to construct phylogenetic trees using the codeml 
programme and a defined tree.  Results are shown in Fig. 4.  For IGFBP1, 2, 4 and 5 the 
branch to NWM is clearly elongated, indicating rapid evolution. In many cases rapid 
evolution is also seen for some of the non-primate outgroups.  In all cases dN/dS is increased 
on the branch to NWM (Table 2), and for IGFBP1 dN/dS is significantly greater than 1.0. In 
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every case the mean dN/dS value was lower for terminal branches to individual NWM 
(Callithrix and Saimiri) than on the branch preceding divergence of these species, indicating 
that after the burst of rapid evolution on the branch leading to NWM, the rate fell. Analysis by 
the branch-sites method [35] showed values of dN/dS exceeding 1.0 on this branch for all 
IGFBPs, but for only IGFBP1 was this statistically significant. 
 
The accelerated evolution on the branch to NWM is most marked for IGFBP1 and IGFBP4 
and is clear from sequence alignments (Fig. 5; equivalent alignments for IGFs 2,3,5 and 6 are 
shown in Supplementary Fig. S4). Notably for both IGFBP1 and IGFBP4, the NWM 
sequences are more different from the human sequence than are those of the phylogenetically 
much more distant prosimian Otolemur (bushbaby) or non-primate species.  Indicated in Fig. 
5 is the division of each protein into 3 domains (in addition to signal peptide), N-domain, L-
domain and C-domain. For IGFBP1 the NWM L-domain is very divergent, and the presence 
of deletions makes accurate alignment difficult. The rapid evolution of the protein on the 
branch to NWM was not due to misalignment in this region, because analysis of just N- and 
C-domains for IGFBP1 by the codeml branch-sites method confirmed dN/dS > 1.0 (Table 2). 
 
For each IGFBP, residues changing on the branch to NWM were identified by the branch-
sites method (Table 2). These residues were distributed across the 3 domains, with no marked 
predominance in any one. A few of the changing sites were identified as involved in IGF1 
binding sites on N- and C-domain, but again without any marked preponderance. Residues 
that were markedly changed in NWM IGFBP1 compared with the human protein included 
five Ser residues subject to phosphorylation, which alters the affinity for IGF [53,54] (only 
one of which is conserved in NWM IGFBP1), and the Arg-Gly-Asp motif near the C-
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terminus which is required for binding of integrin α5β1 and for effects on cell migration [55] 
and which is conserved in other mammals, but not lower vertebrates [56]. 
 
3.6. Specificity of the accelerated evolution in NWM The	  markedly	  accelerated	  evolution	  seen	  on	  the	  lineage	  leading	  to	  NWM	  for	  insulin,	  IGF1,	  IR,	  IGF1R	  and	  several	  IGFBPs	  shows	  specificity	  in	  that	  for	  the	  two	  receptors	  it	  is	  largely	  confined	  to	  the	  ectodomains	  and	  shows	  a	  different	  pattern	  for	  IR	  and	  IGF1R.	  Furthermore,	  it	  is	  not	  seen	  for	  the	  related	  IRRR	  which	  does	  not	  bind	  insulin	  or	  IGFs.	  	  Analysis	  of	  the	  marmoset	  genome	  [28]	  revealed	  37	  genes,	  including	  IGF1R,	  showing	  positive	  selection	  on	  the	  lineage	  leading	  to	  marmoset	  (before	  and	  after	  the	  
Saimiri/Callithrix	  split),	  suggesting	  that	  rapid	  evolution	  on	  this	  lineage	  is	  not	  common.	  To	  assess	  further	  the	  specificity	  of	  the	  accelerated	  evolution	  seen	  here	  a	  number	  of	  additional	  genes	  are	  considered.	  	  
Growth	  hormone	  (GH),	  prolactin	  and	  their	  receptors.	  GH	  and	  prolactin	  are	  involved	  in	  regulation	  of	  growth	  and	  lactation.	  They	  show	  a	  pattern	  of	  episodic	  evolution	  in	  mammals,	  with	  in	  each	  case	  markedly	  accelerated	  	  evolution	  in	  primates,	  but	  preceding	  the	  NWM/OWM-­‐apes	  split	  [57].	  The	  ecds	  of	  the	  GH	  and	  prolactin	  receptors	  show	  a	  corresponding	  episode	  of	  rapid	  change	  [57,58].	  These	  hormones	  thus	  resemble	  insulin,	  IGF1	  and	  their	  receptors	  in	  showing	  episodic	  evolution,	  but	  the	  pattern	  of	  change	  is	  quite	  distinct.	  
	  
Epidermal	  growth	  factor	  (EGF)	  and	  its	  receptor	  (EGFR).	  The	  EGFR	  is	  a	  tyrosine	  kinase	  receptor,	  like	  IR	  and	  IGF1R	  [59].	  EGF	  shows	  accelerated	  evolution/positive	  selection	  on	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the	  lineage	  to	  marmoset	  [28].	  	  Phylogenetic	  analysis	  shows	  no	  corresponding	  	  episode	  of	  rapid	  change	  in	  EGFR,	  either	  for	  the	  whole	  receptor	  or	  the	  ecd	  (Supplementary	  Fig.	  S5).	  	  
Cation-­‐independent	  mannose	  6-­‐phosphate/IGF2	  receptor	  (M6P/IGF2R).	  The	  M6P/IGF2R	  binds	  IGF2	  as	  well	  as	  mannose	  6-­‐phosphate-­‐containing	  glycoproteins,	  probably	  targeting	  the	  growth	  factor	  for	  degradation.	  	  It	  has	  a	  very	  large	  ecd,	  comprising	  15	  domains	  of	  which	  2	  (domains	  11	  and	  13)	  are	  involved	  in	  	  IGF2	  binding	  [60,61].	  	  Phylogenetic	  analysis	  reveals	  no	  marked	  acceleration	  of	  evolution	  on	  the	  lineage	  leading	  to	  NWM	  for	  the	  whole	  receptor	  or	  for	  the	  IGF2-­‐binding	  domains	  (Supplementary	  Fig.	  S6).	  	  
4.	  Conclusions	  	  
Analysis of the marmoset genome [28,29] showed an acceleration in the rate of evolution of 
IGF1R and IGFBP2, and it was suggested that this was related to the reduced size seen in 
callitrichine NWM.  The present study confirms this acceleration, but establishes that it 
largely stopped before divergence of Callithrix and Saimiri, i.e. before the size reduction 
associated with callitrichine evolution.  This episode of accelerated evolution applied 
specifically to  IGF1, insulin, IGF1R, IR and several IGFBPs.  Various factors suggest that 
adaptive evolution was involved, and in the case of the receptors and IGFBP1 this is 
confirmed by the branch-sites analysis. Whether the periods of accelerated evolution 
coincided exactly cannot be established on the basis of the available evidence, but in each 
case the increased rate of evolution started after divergence of NWM from OWM/apes, and 
was largely completed before divergence of Saimiri and Callithrix. It would clearly be a 
remarkable coincidence if all these molecules showed a burst of rapid evolution 
independently on this branch.  It seems likely therefore that coevolution of these structurally- 
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and functionally-related molecules occurred, associated with a change in their roles in 
regulating cellular metabolism and growth.  Further information about the functions of insulin 
and IGFs in NWM is needed in order to be able to assess the physiological significance of this 
change, and such assessment seems desirable in view of the importance of NWM, especially 
the marmoset, as a model for human biology and disease [62]. 
 
As far as can be ascertained the changes that occurred on the lineage leading to NWM mostly 
did not specifically involve alteration of features most clearly involved in biological function, 
including residues directly involved in receptor-ligand interactions, sites where mutation is 
known to cause significant loss of function, or side chains involved in dimerization.  
However, the structural basis of some functional aspects, including for receptors the second 
binding site and negative cooperativity, is poorly understood, and significant changes here 
cannot be excluded. Effects on the formation of heterodimers between IR and IGF1R are 
possible, given the different distributions of changes in their extracellular domains.  
 
The changes occurring on the lineage leading to NWM are in marked contrast to those seen in 
the other group showing accelerated evolution of insulin. In the hystricognath rodents, 
including guinea pig, insulin sequence is markedly variable and different from that in other 
mammals - much more so than is the case for NWM [63-65]. However, here the sequences of 
IGF1 and IGF2 are strongly conserved [66]. There is a small increase in the rate of evolution 
of IR (Figs 1 and 2), but much less than that seen for NWM, and no acceleration of the rate 
for IGF1R.  It has been suggested [67] that the changes in hystricognath insulin were a 
consequence of lack of environmental zinc, normally a component of insulin crystals and 
secretory granules.  This explanation would accord with the observation that the changes in 
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this group are mainly confined to insulin, but is unlikely to apply in the case of NWM, given 
the marked differences in the pattern of variation seen. 
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Tables 
 
Table 1. dN/dS values for phylogenetic trees - IR, IGF1R and IRRR 
 
 dN/dS 
 IR IGF1R IRRR 
 all branches 
except to NWM 
branch to 
NWM 
all branches 
except to NWM 
branch to 
NWM 
all branches 
except to NWM 
branch to 
NWM 
complete CDS 0.032 0.287a 0.031 0.294a 0.089 0.140d 
ecd 0.030 0.399a 0.026 0.410a 0.066 0.079d 
icd 0.024 0.089b 0.032 0.082c 0.125 0.140d 
 
The significance of elevated dN/dS values on the branch to NWM was tested using the 
likelihood ratio test, comparing model 2 in codeml (2 dN/dS ratio) with model 0 (one dN/dS 
ratio) [31,42]. 
a  2xΔlnL =120.2-135.6; P<<0.001 
b  2xΔlnL =6.94 P<0.01 
c  2xΔlnL =4.32 P<0.05 
d  2xΔlnL =0.04-1.72 P>0.1 
 
 
Table 2. dN/dS values for phylogenetic trees - IGFBPs  
 
 dN/dS  
Number of 
sites under 
selection 
all branches 
except to NWM 
branch below 
NWM 
branches to 
Callithrix and 
Saimiri(mean) 
branch below NWM 
from branch-sites 
analysis 
IGFBP1 0.202 2.95*** 0.476 6.82** 84 
IGFBP1 N&C 
domain 
0.128 2.53*** 0.523 8.33** 56 
IGFBP2 0.107 0.422*** 0.061 2.90 20 
IGFBP3 0.088 0.449*** 0.036 2.00 8 
IGFBP4 0.042 0.647*** 0.020 4.45 21 
IGFBP5 0.027 0.415*** 0.018 1.76 14 
IGFBP6 0.250 0.672* 0.016 2.11 11 
 
The significance of elevated dN/dS values on the branch to NWM was tested using the 
likelihood ratio test, comparing model 2 in codeml (2 dN/dS ratio) with model 0 (one dN/dS 
ratio) [31,42]. 
* 2xΔlnL =4.68; P<0.05; *** 2xΔlnL =14.6-70.8; P<0.001 (comparison with all branches 
except to NWM)  
** 2xΔlnL =17.8-20.6; P<0.001 (comparison with 1.0 in branch-sites method) 
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Figure legends 
 
Fig. 1. Phylogenetic trees for IR, IGF1R, IRRR, insulin and IGF1. Trees were based on 
alignments of protein sequences, and constructed using codeml (with a defined tree) to 
determine branch lengths. The branch to NWM is shown as a heavy line. The scale bars show 
mean substitutions per site. Species included are: Homo (man), Pan (chimpanzee), Gorilla 
(gorilla), Pongo (orangutan), Macaca (rhesus macaque), Papio (baboon), Callithrix 
(marmoset), Saimiri (squirrel monkey), Otolemur (bushbaby), Tupaia (tree shrew), 
Oryctolagus (rabbit), Mus (mouse), Cavia (guinea pig), Canis (dog). Full species names are 
given in Supplementary Table S1. 
 
Fig. 2. Phylogenetic trees for extracellular (ecd) and intracellular (icd) domains of IR, IGF1R 
and IRRR. Trees were based on alignments of protein sequences, and constructed using 
codeml (with a defined tree), to determine branch lengths. The branch to NWM is shown as a 
heavy line. The scale bars show mean substitutions per site. Species included are indicated in 
Fig. 1 legend. 
 
Fig. 3. Distribution of substitutions on the ectodomains of IR and IGF1R. Structures were 
produced using Pymol, and the 3D structure of the IR ectodomain ([16], pdb structure 2DTG, 
single monomer, Fab structures excluded). Residues shown in space-fill mode are those 
which change on the lineage to NWM. Note that the insertion domain (residues 656-754, 
including αCT), is not shown in the crystal structure. LR1 is largely located behind CR. 
Numbers following domain names are the numbers of changes on the branch to NWM for that 
domain. 
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Fig 4. Phylogenetic trees for IGFBP1-6. Trees were based on alignments of mature protein 
sequences, and constructed using codeml (with a defined tree) to determine branch lengths. 
The branch to NWM is shown as a heavy line.  Scale bars indicate mean substitutions per site. 
Species included are indicated in Fig. 1 legend, plus Sus (pig), used where Canis sequence not 
available. 
 
Fig. 5. Sequence alignments for IGFBP1 and IGFBP4. The human sequence is shown in full, 
identical residues are shown by . and gaps by -.  Number of differences from human are 
shown at the end of of each sequence. The N- and C-domains are shaded grey. Species 
included are indicated in Fig. 1 legend. 
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